A Phase I Study to Evaluate the Safety and Efficacy of RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer
Latest Information Update: 01 Sep 2023
At a glance
- Drugs Gemcitabine (Primary) ; RP 72 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Rise Biopharmaceuticals
Most Recent Events
- 27 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2025.
- 27 Mar 2023 Planned primary completion date changed from 31 Oct 2022 to 31 Oct 2024.
- 07 May 2021 Status changed from not yet recruiting to recruiting.